Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lufepirsen - OcuNexus Therapeutics

Next Previous
Drug Profile

Lufepirsen - OcuNexus Therapeutics

Alternative Names: Antisense deoxynucleotide oligomer - OcuNexus Therapeutics; Antisense oligonucleotide compound - OcuNexus Therapeutics; CODA-001; Connexin43 antisense oligonucleotide - OcuNexus Therapeutics; Nexagon

Latest Information Update: 08 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CoDa Therapeutics (NZ); CoDa Therapeutics Inc
  • Developer CoDa Therapeutics Inc; Eyevance Pharmaceuticals; OcuNexus Therapeutics
  • Class Antisense oligonucleotides; Antiulcers; Eye disorder therapies; Foot disorder therapies; Skin disorder therapies
  • Mechanism of Action Connexin 43 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Corneal injuries
  • No development reported Diabetic foot ulcer; Leg ulcer; Wounds

Most Recent Events

  • 31 Jul 2023 Phase-II/III clinical trials in Corneal injuries (In adolescents, In children, In the elderly, In adults) in USA (Opthalmic) (NCT05966493)
  • 26 Sep 2022 Lufepirsen is still in phase II trial for Corneal injuries (In adolescents, In children, In the elderly, In adults) in India, USA (Topical) (NCT04081103) (CTRI2019-08-020943)
  • 12 Jan 2022 Amber Ophthalmics has patent protection for lufepirsen (Amber Ophthalmics website, January 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top